Attached files
file | filename |
---|---|
EX-99.1 - Bohai Pharmaceuticals Group, Inc. | v205533_ex99-1.htm |
EX-10.1 - Bohai Pharmaceuticals Group, Inc. | v205533_ex10-1.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or Section 15(d) of the Securities Exchange Act of
1934
Date of
Report (Date of Earliest Event Reported): December 9,
2010
Bohai
Pharmaceuticals Group, Inc.
(Exact
name of registrant as specified in its charter)
Nevada
|
000-53401
|
98-0588402
|
||
(State
or other jurisdiction
of
incorporation)
|
(Commission
File
Number)
|
(IRS
Employer
Identification
No.)
|
c/o
Yantai Bohai Pharmaceuticals Group Co. Ltd.
No.
9 Daxin Road, Zhifu District
Yantai,
Shandong Province, China 264000
|
(Address
of principal executive offices)
|
Registrant’s
telephone number, including area code: +86(535)-685-7928
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation to the registrant under any of the following
provisions:
o
|
Written
communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b))
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR 240.13e-4(c))
|
Item 1.01
|
Entry
into a Material Definitive
Agreement.
|
On
December 9, 2010, Bohai Pharmaceuticals Group, Inc. (the “Company”) entered into
an Transfer Agreement of Intangible Assets (the “Transfer Agreement”) with Shandong Daxin Microbiology Pharmaceutical
Industry Co., Ltd., a company incorporated in the People’s Republic of China
(“Daxin”), pursuant to which Daxin agreed to transfer to the Company all rights
and title in and to 14 Drug Approval Numbers (“DANs”) for 14 traditional Chinese
medicines, which DANs were previously issued to Daxin by the Shandong Branch of
the State Food and Drug Administration of China (“SFDA”). The
aggregate purchase price is RMB 48 million (approximately US$7,200,000), of
which RMB 20 million (approximately US$3,000,000) will be paid within 15 days
after the execution of the Transfer Agreement and the remaining balance will be
paid on or before January 31, 2011. As of the date of the execution
of the Transfer Agreement, the proposed transfer of the aforementioned 14 DANs
has been approved by Shandong SFDA.
As a
result of the transfer of the DANs to the Company, the Company will have the
right, on a non-exclusive basis, to produce the traditional Chinese medicines
covered by the DANs, which are as follows:
Number
|
Name
of the Medicines
|
DANs
|
1
|
Yinqiao
Detoxification Pellet
|
Z37020715
|
2
|
Tianwang
heart nourishing Pellet
|
Z37020714
|
3
|
Tongxuan
lung Pellet
|
Z37020717
|
4
|
Ruyi
Jinhuang Powder
|
Z37020709
|
5
|
Xiaohuoluo
Pellet
|
Z37020711
|
6
|
Dieda
Pellet
|
Z37020723
|
7
|
Qipi
Pellet
|
Z37020685
|
8
|
Ginseng
Guipi Pellet
|
Z37020716
|
9
|
Spleen
Pellet
|
Z37020712
|
10
|
Jiufen
Powder
|
Z37020683
|
11
|
Wu
Zi Yan Zong Pellet
|
Z37020707
|
12
|
Qingwen
Detoxification Pellet
|
Z37020708
|
13
|
Wuhu
Powder
|
Z37020710
|
14
|
Hawthorn
Pellet
|
Z37020713
|
The
foregoing medicines are in addition to the 29 traditional Chinese medicine
products that the Company is authorized to produce, of which 15 are currently in
production.
A copy of the Transfer Agreement is attached
hereto as exhibit 10.1. The foregoing description of the Transfer Agreement is qualified in its
entirety by reference to such exhibit.
Item
8.01 Other Events.
On
December 14, 2010, the Company issued a press release announcing the signing of
the Transfer Agreement. A copy of the press release is filed herewith
as Exhibit 99.1.
Item
9.01 Financial Statements and Exhibits
(d) Exhibits
|
10.1
|
Unofficial
English Translation of the Intangible Assets Transfer Agreement, dated
December 9, 2010, by and between the Company and Shandong Daxin
Microbiology Pharmaceutical Industry Co.,
Ltd.
|
|
99.1
|
Press
Release, dated December 14, 2010, regarding the Company’s agreement with
Shandong Daxin Microbiology Pharmaceutical Industry Co.,
Ltd.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
Bohai
Pharmaceuticals Group, Inc.
|
|||
December
14, 2010
|
By:
|
/s/ Gene Hsiao | |
Name: Gene Hsiao | |||
Title: Chief Financial Officer | |||